Skip to main content

Table 3 Polysensitization

From: Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry

Characteristic No polysensitization Polysensitization p
Mean/n/% SD Median IQR Mean/n/% SD Median IQR
General
 n (male/female) 124 (50/74)     37 (15/22)     0.981
 Age (years) 53.36 10.94 52.00 17.00 51.62 12.68 52.00 18.00 0.546
 Weight (kg) 77.64 17.23 75.00 24.50 80.27 17.88 80.00 27.00 0.385
 Total IgE (IU/ml) 328.83 294.71 204.50 377.00 418.84 358.10 304.00 444.00 0.178
 Omalizumab dose (mg/month) 483.87 247.80 450.00 300.00 419.59 240.74 300.00 300.00 0.109
Baseline
 FeNO (ppb) 51.26 50.23 38.00 48.00 50.14 42.93 38.00 59.00 0.891
 ACT (points) 12.19 3.68 12.00 5.50 13.73 4.23 14.00 7.00 0.065
 FEV1 (%pred) 63.61 18.65 66.50 24.00 63.49 16.83 61.00 15.00 0.576
 Severe exacerbations (n/year) 2.98 4.89 2.00 3.00 2.08 3.14 1.00 1.00 0.080
 Systemic corticosteroids (n/%) 97 (78.2%)     22 (59.5%)     0.023
 Prednisone (mg/day) 13.29 14.86 7.00 15.00 15.82 20.71 10.00 15.00 0.239
Final
 FeNO (ppb) 37.01 37.66 24.00 26.00 28.78 32.50 20.00 32.00 0.114
 ACT (points) 18.63 4.81 20.00 7.00 17.53 4.48 17.00 7.50 0.159
 FEV1 (%pred) 72.43 23.14 76.00 30.00 71.31 18.71 68.50 22.50 0.560
 Severe exacerbations (n/year) 0.85 2.46 0.00 1.00 1.25 3.01 0.00 1.00 0.581
 Systemic corticosteroids (n/%) 54 (43.5%)     14 (20.6%)     0.537
 Prednisone (mg/day) 7.94 8.95 5.00 8.00 13.43 17.87 5.00 5.00 0.308
  1. Baseline and final characteristics of responders with regards to polysensitization (per protocol analysis, Wilcoxon signed-rank test, and Chi squared test)